Chat with Filing

Ask questions about this document
Please log in or register to use the chat feature. Please register first.
RNS - EVOTEC, SENSYNE HEALTH, THE UNIVERSITY OF OXFORD, OSI, AND OUI CREATE NEW BRIDGE PARTNERSHIP 'LAB10X' IN DIGITAL HEALTH

Company: Evotec SE Date: 2019-06-24 Language: English Register to download
Loading document preview...
Document Preview Not Available

The file type (.html) cannot be displayed directly here.
Open Original File
Error loading document preview. Please try the 'Open Original File' link.
You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:
Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon
 News Details

Corporate | 24 June 2019 07:54

#   

EVOTEC, SENSYNE HEALTH, THE UNIVERSITY OF OXFORD, OSI, AND OUI CREATE NEW BRIDGE PARTNERSHIP ‘LAB10X’ IN DIGITAL HEALTH

DGAP-News: Evotec SE / Key word(s): Contract  

  

24.06.2019 / 07:54  

The issuer is solely responsible for the content of this announcement.  

  

- - -

**–** *LAB10X FOCUSES ON ACCELERATING DATA-DRIVEN HEALTHCARE SOLUTIONS POWERED BY ARTIFICIAL INTELLIGENCE (“AI”)  

– GOAL IS TO ACCELERATE PROOF-OF-CONCEPT IN DIGITAL HEALTH*

  

**Hamburg, Germany, and Oxford, UK, 24 June 2019:** Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a new strategic partnership with the British clinical AI technology company Sensyne Health plc (LSE:SENS) (“Sensyne”), the University of Oxford, Oxford University Innovation Ltd (“OUI”, the university’s research commercialisation company), and Oxford Sciences Innovation (“OSI”, the world’s largest IP investment company dedicated to a single university) to fund a new BRIDGE called LAB10x.

This BRIDGE is aimed at accelerating the translation of research in the fields of clinical artificial intelligence and digital health at Oxford into forming new companies applying breakthrough digital solutions, clinical AI algorithms and accelerated data-driven drug discovery and development.

Under the terms of the agreement, digital health projects will be sourced exclusively from Oxford researchers via OUI and will be aided by an expert in residence seconded by Sensyne to the LAB10x initiative and embedded in the university. The technologies developed by LAB10x will be applied to generate and analyse anonymised patient datasets to improve patient outcomes and accelerate medical research and pharmaceutical R&D.

The partnership brings together Sensyne’s strength in clinical AI and digital health with Evotec’s leading drug discovery and development expertise to leverage the world-class science at Oxford. The University of Oxford was recently ranked as world No 1 in medical science, engineering science and computer science, the three fields most relevant to the focus of LAB10x.

LAB10x will be supported by a fund of approx. £ 5 m (approx. EUR 5.6 m) for an initial period of three years.

Evotec will provide access to its drug discovery expertise while Sensyne will exclusively contribute its clinical AI and digital health expertise and regulated software development and data analysis environment under its Quality Management System to select projects and develop them to the point of commercial proof of concept.

Evotec and Sensyne will be entitled to equity in new LAB10x spin-out companies together with Oxford University and its academic researchers. Both companies, together with OSI, will have the right to co-invest in seed financing rounds. Where company creation is not the chosen commercial path, Sensyne will have the right to acquire a license to IP generated by the selected projects. Sensyne and Evotec are also exploring other opportunities for collaboration.

**Dr Werner Lanthaler, Chief Executive Officer of Evotec, said:** “The medicine of the future will see radical change, driven by the continuing expansion of drug discovery technologies like artificial intelligence and healthcare mega trends like digital health. Evotec and our partners will continue to invest in these areas and we are pleased to launch LAB10x with Sensyne, OSI, OUI, and the University of Oxford. Today’s announcement demonstrates the power of forming public-private partnerships in drug discovery to create the next generation of medicines in an effective and efficient manner.”

**Lord (Paul) Drayson, CEO of Sensyne Health, said** : “LAB10x will leverage Sensyne’s expertise in digital health and clinical AI, our regulated development environment and our unique partnership model with the University of Oxford and NHS Trusts, to ensure the science is brought through to application as quickly and efficiently as possible – delivering benefits for patients and creating significant value.”

**Dr Matt Perkins, CEO of Oxford University Innovation, said:** “Building on LAB282, the pioneering public-private drug discovery partnership model that has now been replicated around the world, LAB10x aims to combine the rapidly growing body of world class research in data-driven health innovation at Oxford with expertise, resources and an industry standard development framework for digital health innovations. Today’s announcement provides a solution to a significant unmet need that has the potential to maximise the global impact of Oxford’s research and expertise, leading to better healthcare technologies, disease insights, treatments and cures.”

**Professor Gavin Screaton, Head of Medical Sciences Division, University of Oxford, said:** “Digital health solutions and data-driven insights often require a multidisciplinary approach, bringing together clinicians, medical researchers, engineers and computer scientists. With world leaders in these fields, it is no surprise that Oxford University is generating a wealth of exciting innovations in this space and it is vital that this is matched by high quality translational support which increases the likelihood of future societal benefits. LAB10x has huge potential to maximise the impact of medical research and innovation in Oxford.”

The LAB10x name was chosen by the partners collectively to signify how critical data-driven healthcare can be accelerated from concept to innovation ten times faster, as the result of the cumulative experience of the LAB10x partners involved and by applying an agile development methodology within a regulated framework.

**About digital health**  

With the rapid progress being made in artificial intelligence (AI) and digital health, there is a clear need to better understand these technologies and how they will ultimately benefit patients and the healthcare system. Digital health is the convergence of digital technologies with health, healthcare, living, and society to enhance the efficiency of healthcare delivery and make medicines more personalised. A digital therapeutic delivers evidence-based therapeutic interventions to patients that are driven by high quality software programmes to prevent, manage, or treat a medical disorder or disease. They are used independently or together with medications, devices or other therapies to optimise patient care and overall health outcomes.

**About Evotec’s BRIDGE model: Partnering to accelerate innovation**  

Evotec has created a new paradigm to translate early-stage academic research to drug discovery and development called “BRIDGE” (Biomedical Research, Innovation & Development Generation Efficiency), an integrated fund and award framework to tap into exciting academic science to accelerate the formation of spin-out companies and generate partnerships with Pharma and biotech. Through these efforts, Evotec has defined a new formula for fast-track early-stage drug discovery. Since the launch of the BRIDGE model in 2016, Evotec has formed and funded five partnerships, termed LAB282, LAB150, LAB591, LAB031, and LAB10x.

*ABOUT SENSYNE HEALTH  

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.*

*Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).*

***Sensyne contact**  

  

Sensyne Health (* **[WWW.SENSYNEHEALTH.COM](https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ca9c3d144af58756a75db19087e881ce&application_id=829221&site_id=news_data&application_name=news)** *)  

+44 (0) 330 058 1845  

Lord (Paul) Drayson PhD FREng, Chief Executive Officer  

Lorimer Headley, Chief Financial Officer  

Julia Wilson, Director of Investor Relations*

*Consilium Strategic Communications  

+44 20 3709 5700  

Mary-Jane Elliott  

Sukaina Virji  

Melissa Gardiner*

*ABOUT THE UNIVERSITY OF OXFORD  

Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the third year running, and at the heart of this success is our ground-breaking research and innovation.  

Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions.  

Oxford has also been ranked as the world’s best institution for medical and health teaching and research by Times Higher Education for eight consecutive years.*

*ABOUT OXFORD SCIENCES INNOVATION  

Oxford Sciences Innovation (OSI) is Oxford’s early stage venture partner, dedicated to investing in new and emerging platforms driven by deep science and technology. OSI is guided and powered by some of the world’s leading organisations, with £ 600 m raised from GV, Sequoia, Tencent, The Wellcome Trust, Temasek and several others. Since their first investment in 2015, OSI has been helping Oxford scientists address the world’s leading challenges, from infectious disease to sustainable energy*

*ABOUT OXFORD UNIVERSITY INNOVATION  

Oxford University Innovation supports innovation activities across all University Divisions, managing technology transfer and consulting activities, and creating a world-leading innovation ecosystem, with Oxford University at its heart.  

We provide access to technology from Oxford researchers through intellectual property licensing, spinout company formation and material sales, and to academic expertise through our Consulting Services team. The New Venture Support & Funding team supports investors or donors with an interest in early-stage ventures and manages the Oxford Angels Network.  

Our Startup Incubator supports members and ex-members of the University who wish to start or grow entrepreneur-driven ventures that are not University spinouts.  

Oxford University Innovation is the highest university patent filer in the UK and is ranked 1st in the UK for university spinouts, having created over 170 new companies since 1988. Over a third of these companies have been created in the past three years. .In the 2016/17 financial year we completed more than 50 licenses and consulting agreements every month. For updates on innovations from Oxford, follow Oxford University Innovation on* [LinkedIn](https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=d2a8d89c2111607d5c05bace7f7e03e2&application_id=829221&site_id=news_data&application_name=news) *and* [Twitter](https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=af30849cc9338cc575dcfb22aa10dac3&application_id=829221&site_id=news_data&application_name=news) *or subscribe at* [http://innovation.ox.ac.uk/about/contact-us/#enquiry](https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=a3d5ebccdb47d4c29f9746daa6b0471c&application_id=829221&site_id=news_data&application_name=news)

*ABOUT EVOTEC SE  

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,600 employees provide the highest quality* *stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product* *opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including, Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to* [www.evotec.com](https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=d9f30c4aeb65d3276d5bd878be7dc75c&application_id=829221&site_id=news_data&application_name=news) *and follow us on Twitter* [@Evotec](https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=174f1f6538cbb01e3ef3386d1481ea5f&application_id=829221&site_id=news_data&application_name=news) *.*

Contact Evotec AG:  

Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, [gabriele.hansen@evotec.com](mailto:gabriele.hansen@evotec.com)  

  

*FORWARD LOOKING STATEMENTS*  

*Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*

  

- - -

24.06.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.  

The issuer is solely responsible for the content of this announcement.  

  

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.dgap.de  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | Evotec SE |
|     | Manfred Eigen Campus / Essener Bogen 7 |
|     | 22419 Hamburg |
|     | Germany |
| Phone: | +49 (0)40 560 81-0 |
| Fax: | +49 (0)40 560 81-222 |
| E-mail: | info@evotec.com |
| Internet: | www.evotec.com |
| ISIN: | DE0005664809 |
| WKN: | 566480 |
| Indices: | MDAX, TecDAX |
| Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 829221 |

  

|     |     |
| --- | --- |
|     |     |
| End of News | DGAP News Service |

![show this](https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=829221&application_name=news&site_id=news_data)